Followers | 72 |
Posts | 4385 |
Boards Moderated | 2 |
Alias Born | 08/21/2015 |
Wednesday, November 16, 2022 12:35:15 PM
Based on these high-impact publications the view was that LSD effects cannot be antagonized and it was therefore not obvious that this can be done with ketanserin. Based on pharmacokinetic-pharmacodynamic modeling data and the present human study the present patent application showed an unexpected effect of ketanserin to reverse the LSD response. The fact that ketanserin has been used in preclinical experiments and in humans to prevent the response to LSD is not an obvious indication of antagonism when used after LSD in the light of the scientific published data. There was no preclinical or clinical data using ketanserin to reverse LSD responses in vivo prior to the present patent application.
Therefore, the combination of Kraehenmann, et al. and Peters, et al. does not disclose or suggest the present invention, and the unexpected results overcome the prima facie obvious rejection.
Since neither the cited references alone or in combination with knowledge in the art suggest the currently claimed invention, it is consequently respectfully submitted that the claims are clearly patentable over the combination, even if the combination were to be applied in opposition to applicable law, and reconsideration of the rejection is respectfully requested.
The remaining dependent claims not specifically discussed herein are ultimately dependent upon the independent claims. References as applied against these dependent claims do not make up for the deficiencies of those references as discussed above, and the prior art references do not disclose the characterizing features of the independent claims discussed above. Hence, it is respectfully submitted that all of the pending claims are patentable over the prior art.
In conclusion, it is respectfully requested that the present amendment be entered in order to place the application in condition for allowance, which allowance is respectfully requested.
Recent MNMD News
- MindMed Announces New Employee Inducement Grants • Business Wire • 09/09/2024 08:01:00 PM
- MindMed to Participate in September Investor Conferences • Business Wire • 09/04/2024 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/22/2024 08:30:13 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/21/2024 01:14:04 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/13/2024 11:25:20 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/13/2024 11:15:08 AM
- MindMed Reports Second Quarter 2024 Financial Results and Business Updates • Business Wire • 08/13/2024 11:00:00 AM
- U.S. Futures Climb Before Inflation Data; Oil Slips on OPEC Demand Cut • IH Market News • 08/13/2024 09:45:01 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/12/2024 12:38:22 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 08/12/2024 10:11:49 AM
- Mind Medicine (MindMed) Inc. Announces Pricing of Public Offering • Business Wire • 08/09/2024 12:44:00 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 08/09/2024 10:04:54 AM
- Mind Medicine (MindMed) Inc. Announces Proposed Public Offering • Business Wire • 08/09/2024 10:00:00 AM
- MindMed to Present at Canaccord Genuity’s 44th Annual Growth Conference • Business Wire • 08/06/2024 08:01:00 PM
- MindMed to Host Conference Call and Webcast to Discuss Second Quarter 2024 Financial Results and Provide Business Update • Business Wire • 08/06/2024 11:00:00 AM
- MindMed Appoints Stephanie Fagan as Chief Corporate Affairs Officer • Business Wire • 07/29/2024 11:00:00 AM
- MindMed Announces Issuance of New Patent for MM120 Orally Disintegrating Tablet (ODT) • Business Wire • 07/17/2024 11:00:00 AM
- MindMed to be Included in Russell 2000® and Russell 3000® Indexes • Business Wire • 06/28/2024 11:00:00 AM
- MindMed to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference • Business Wire • 06/21/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/20/2024 12:00:10 PM
- MindMed Announces Constructive End-of-Phase 2 Meeting with U.S. FDA for MM120 in Generalized Anxiety Disorder (GAD) • Business Wire • 06/20/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/11/2024 08:30:10 PM
- MindMed to Participate in June Conferences • Business Wire • 05/28/2024 11:00:00 AM
- MindMed to Participate at May Investor Conferences • Business Wire • 05/09/2024 08:01:00 PM
- New Studies Presented at the International Society for Health Economics and Outcomes Research Meeting (ISPOR 24) Show Growing Burden and Impact of Generalized Anxiety Disorder (GAD) in the US • Business Wire • 05/09/2024 12:00:00 PM
FEATURED Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • Sep 24, 2024 8:50 AM
FEATURED Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM